News | February 25, 2025
Biocon Biologics launches Yesintek Biosimilar to Stelara in US
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Subscribe To Our Newsletter & Stay Updated
